The Independent Data Monitoring Committee completed an interim analysis of Exelixis Inc.'s (Nasdaq: EXEL) COMET-1 phase 3 pivotal trial and recommended that the trial proceed to final analysis but shares of Exelixis plummeted $2.27 to $4.17.
Exelixis Plunges
March 26, 2014 at 13:15 PM EDT
